|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
WO2010115589A1
(en)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
MA41375A
(fr)
*
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
AR103477A1
(es)
*
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
RU2765242C2
(ru)
|
2015-08-07 |
2022-01-27 |
Имаджинаб, Инк. |
Антигенсвязывающие конструкции против молекул-мишеней
|
|
EP3150636A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
WO2017117464A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
NZ756132A
(en)
*
|
2017-03-10 |
2022-02-25 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
|
WO2018184966A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
|
JP6871415B2
(ja)
|
2017-04-05 |
2021-05-12 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｌａｇ３抗体
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
US20200157224A1
(en)
*
|
2017-06-25 |
2020-05-21 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
|
JP2021508471A
(ja)
|
2017-12-29 |
2021-03-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
安定化された免疫グロブリンドメイン
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
BR112020017872A2
(pt)
|
2018-03-02 |
2020-12-22 |
Kodiak Sciences Inc. |
Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3775184B1
(en)
|
2018-03-29 |
2025-12-10 |
F. Hoffmann-La Roche AG |
Modulating lactogenic activity in mammalian cells
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
CN119708249A
(zh)
|
2018-12-21 |
2025-03-28 |
豪夫迈·罗氏有限公司 |
与VEGF和IL-1β结合的抗体及其使用方法
|
|
WO2020127619A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
BR112021012338A2
(pt)
*
|
2018-12-24 |
2021-09-14 |
Sanofi |
Proteínas de ligação multiespecíficas com domínios fab mutantes
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
CN114126714A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
AU2020224154B2
(en)
|
2019-02-21 |
2025-05-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
BR112021021972A2
(pt)
|
2019-05-03 |
2021-12-21 |
Hoffmann La Roche |
Métodos de redução de uma taxa de atividade de hidrólise enzimática, de redução do nível de uma ou mais enzimas hidrolíticas e de redução da degradação de um polissorbato, composições farmacêuticas e composições de porção de anticorpo formulada
|
|
JP7760377B2
(ja)
*
|
2019-05-09 |
2025-10-27 |
メルス ナムローゼ フェンノートシャップ |
タンパク質を多量体化する変異体ドメイン及びその分離
|
|
SG11202110525QA
(en)
*
|
2019-05-09 |
2021-10-28 |
Genentech Inc |
Methods of making antibodies
|
|
BR112021025029A2
(pt)
|
2019-06-13 |
2022-01-25 |
Allogene Therapeutics Inc |
Anticorpos anti-talen e seus usos
|
|
AU2020306672B2
(en)
|
2019-06-26 |
2023-08-24 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with SIRT-1 gene knockout
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
CN114174342B
(zh)
|
2019-07-31 |
2024-08-16 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
US12312414B2
(en)
|
2019-09-18 |
2025-05-27 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3152314A1
(en)
|
2019-11-15 |
2021-05-20 |
Andrea ALLMENDINGER |
Prevention of visible particle formation in aqueous protein solutions
|
|
WO2021122875A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/mage-a4
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
MX2022007746A
(es)
|
2019-12-23 |
2022-10-07 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso.
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
JP2023510382A
(ja)
|
2020-01-15 |
2023-03-13 |
エフ． ホフマン－ラ ロシュ アーゲー |
組換えタンパク質製造プロセスから不純物を減少させる方法
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
CA3169908A1
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
WO2021198034A1
(en)
|
2020-03-30 |
2021-10-07 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf and pdgf-b and methods of use
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2021228917A1
(en)
|
2020-05-15 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in parenteral protein solutions
|
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
|
CA3184495A1
(en)
|
2020-06-08 |
2021-12-16 |
F. Hoffmann-La Roche Ag |
Anti-hbv antibodies and methods of use
|
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
|
MX2022015204A
(es)
|
2020-06-19 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3.
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
IL298610A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies binding to cd3 and folr1
|
|
KR20230026491A
(ko)
|
2020-06-24 |
2023-02-24 |
제넨테크, 인크. |
아폽토시스 내성 세포주
|
|
WO2022006327A1
(en)
|
2020-07-01 |
2022-01-06 |
Silverback Therapeutics, Inc. |
Anti-asgr1 antibody conjugates and uses thereof
|
|
CN116133689A
(zh)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
EP4204450A4
(en)
|
2020-08-26 |
2024-11-13 |
Marengo Therapeutics, Inc. |
MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
|
|
EP4204096A4
(en)
|
2020-08-26 |
2024-10-02 |
Marengo Therapeutics, Inc. |
ANTIBODY MOLECULES BINDING TO NKP30 AND USES THEREOF
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
|
|
AU2021335509B2
(en)
|
2020-09-04 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Antibody that binds to VEGF-A and ANG2 and methods of use
|
|
KR20230068415A
(ko)
|
2020-09-24 |
2023-05-17 |
에프. 호프만-라 로슈 아게 |
유전자 녹아웃을 갖는 포유류 세포주
|
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
|
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
Anti-hla-g antibodies and use thereof
|
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
CN117597359A
(zh)
|
2021-04-08 |
2024-02-23 |
马伦戈治疗公司 |
与tcr结合的多功能分子及其用途
|
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
|
AU2022295067A1
(en)
|
2021-06-18 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
US20250215103A1
(en)
|
2021-08-03 |
2025-07-03 |
Hoffmann-La Roche Inc. |
Bispecific antibodies and methods of use
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
CN118401674A
(zh)
|
2021-12-21 |
2024-07-26 |
豪夫迈·罗氏有限公司 |
用于确定水解活性的方法
|
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗ｎｏｔｃｈ２抗體及結合物及其使用方法
|
|
EP4511388A1
(en)
|
2022-04-19 |
2025-02-26 |
F. Hoffmann-La Roche AG |
Improved production cells
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
PE20250796A1
(es)
|
2022-07-22 |
2025-03-14 |
Genentech Inc |
Moleculas de union al antigeno anti-steap1 y sus usos
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
CN120019277A
(zh)
|
2022-10-12 |
2025-05-16 |
豪夫迈·罗氏有限公司 |
用于对细胞进行分类的方法
|
|
AU2023386575A1
(en)
|
2022-11-23 |
2025-03-27 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
|
CN119998314A
(zh)
|
2022-12-08 |
2025-05-13 |
长春百克生物科技股份公司 |
特异性结合rsv的抗体
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4655322A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Antibodies binding to csf1r and cd3
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
US20240327522A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
CN121127493A
(zh)
|
2023-05-08 |
2025-12-12 |
豪夫迈·罗氏有限公司 |
靶向干扰素 α 融合蛋白及使用方法
|
|
US20250011450A1
(en)
|
2023-06-22 |
2025-01-09 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|